Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | FABP7 | O15540 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15146937 | 0.91 | KMT2A (0.59) | KMT2AEPHX2SMN1; SMN2LMNACASP3 | |
| SCHEMBL22279559 | 0.91 | KMT2A (0.59) | KMT2AEPHX2SMN1; SMN2LMNACASP3 | |
| SCHEMBL17971009 | 0.91 | KMT2A (0.59) | KMT2AEPHX2SMN1; SMN2LMNACASP3 | |
| SCHEMBL12806526 | 0.89 | KMT2A (0.55) | KMT2AEPHX2SMN1; SMN2LMNACASP3 | |
| SCHEMBL30277387 | 0.89 | KMT2A (0.55) | KMT2AEPHX2SMN1; SMN2LMNACASP3 | |
| SCHEMBL23042742 | 0.89 | KMT2A (0.57) | KMT2AEPHX2SMN1; SMN2LMNACASP3 | |
| SCHEMBL4557019 | 0.89 | KMT2A (0.63) | KMT2AEPHX2SMN1; SMN2LMNACASP3 | |
| SCHEMBL178765 | 0.89 | KMT2A (0.63) | KMT2AEPHX2SMN1; SMN2LMNACASP3 | |
| SCHEMBL1593608 | 0.89 | KMT2A (0.63) | KMT2AEPHX2SMN1; SMN2LMNACASP3 | |
| SCHEMBL4557247 | 0.89 | KMT2A (0.63) | KMT2AEPHX2SMN1; SMN2LMNACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20150150998-A1 | METHODS FOR OXIME CONJUGATION TO KETONE-MODIFIED POLYPEPTIDES | NOVARTIS AG (CH) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | KMT2A 4295/4885EPHX2 382/4885SMN1; SMN2 3485/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | KMT2A 4295/4885EPHX2 382/4885SMN1; SMN2 3485/4885 |
| US-20150150998-A1 | METHODS FOR OXIME CONJUGATION TO KETONE-MODIFIED POLYPEPTIDES | PTMS, CRYAA, KRTCAP2 | KMT2A 635/4885EPHX2 1044/4885SMN1; SMN2 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.